Canada Markets open in 5 hrs 7 mins

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
56.97-2.13 (-3.60%)
At close: 04:00PM EST
56.21 -0.76 (-1.33%)
After hours: 05:20PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close59.10
Open57.73
Bid59.10 x 1400
Ask59.49 x 1800
Day's Range55.50 - 57.77
52 Week Range46.48 - 64.21
Volume10,423,761
Avg. Volume4,713,234
Market Cap176.539B
Beta (5Y Monthly)0.19
PE Ratio (TTM)105.21
EPS (TTM)0.54
Earnings DateN/A
Forward Dividend & Yield1.40 (2.41%)
Ex-Dividend DateAug. 12, 2021
1y Target Est67.68
  • Reuters

    UPDATE 2-Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - study

    A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac's CoronaVac shot, a study has found. The study found that CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants, researchers from Brazil and Oxford University said https://www.ox.ac.uk/news/2022-01-24-mixed-vaccine-schedules-offer-strong-booster-responses-after-two-doses-coronavac on Monday. China-based Sinovac's vaccine uses an inactivated version of a coronavirus strain that was isolated from a patient in China.

  • Business Wire

    Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

    WILMINGTON, Del., January 24, 2022--Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition.

  • The Telegraph

    Patients to receive new cancer drugs faster under Brexit rules shake-up

    Patients will receive new cancer drugs more quickly following post-Brexit changes to the regulatory oversight of pharmaceuticals.